Zealand Pharma revenue and financials
kr 246.90Change from previous close: −1.67%Absolute change: −kr 4.20
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 406 | -672 | -1,043 | -444 | 8,520 | — |
| Depreciation and amortization | 11.0 | 10.0 | 8.0 | 7.4 | 7.0 | — |
| Capital expenditure | -14.0 | -11.0 | -49.9 | -3.1 | -8.0 | — |
| Investing cash flow | 223 | -116 | -373 | -855 | -1,575 | — |
| Financing cash flow | -435 | -8.0 | 10.6 | -77.8 | -310 | — |
| Share repurchases | — | — | 0.0 | -75.2 | — | — |
| Debt issued | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Effect of exchange rates | -5.0 | 68.0 | 9.5 | 106 | -167 | — |
| Net change in cash | 194 | -796 | -1,406 | -1,377 | 6,635 | — |
| Free cash flow | 392 | -683 | -1,093 | -447 | 8,512 | — |